News | February 25, 2026
FDA greenlights Biocon’s Liraglutide for chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The data highlights its RSV vaccine cuts hospitalizations in older adults
Subscribe To Our Newsletter & Stay Updated
